glp1InjectableNot FDA-approvedPrescription only (US)First approved in China in 2026 for chronic weight management; not approved by the FDA or EMA
EcnoglutideBenefits, Dosage & Interactions
Ecnoglutide is an investigational drug belonging to the class of glucagon-like peptide-1 (GLP-1) receptor agonists. These compounds mimic the action of natural GLP-1, a hormone released from the gut in response to food intake. Research on Ecnoglutide focuses on weight loss and blood sugar control.
Researched by DoseRoutine R&D TeamReviewed for accuracy by Nicholas Alexander, RSELast updated
Evidence: Strong — 1 human randomized trial published.
Evidence strengthStrong · 4/4
PreclinicalStrong human evidence
1 human randomized trial published.
Plasma half-life
124–138 h
Default unit
mg
What published protocols report
Ranges documented in the literature, shown for reference. DoseRoutine does not recommend an amount — your prescriber or the product label sets the dose.
- Route studied
- Subcutaneous injection, in the phase I drug-interaction trial cited here[2]
- Frequency
- Once weekly, in the phase I trial cited here[2]
Reported for Ecnoglutide in the cited sources. Published ranges are not dosing advice.
References & evidence
Documents the Ecnoglutide entry is written from. Each number matches an inline marker above.
- [1]Ecnoglutide: First ApprovalsShirley M · Drugs · 2026 · Peer-reviewed · PMID 42412371
- [2]Effect of a Novel GLP-1 Analogue Ecnoglutide on the Pharmacokinetics of Rosuvastatin and Digoxin in Healthy ParticipantsLi F, Du C, Yu Q, et al. · Diabetes, Obesity and Metabolism · 2026 · Peer-reviewed · PMID 42310888
- [3]Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysisNong K, Shi Q, Xie X, et al. · BMJ · 2026 · Peer-reviewed · PMID 42419792
How to track Ecnoglutide doses
Ecnoglutide is tracked as a protocol rather than a single reminder: a vial with a concentration, a schedule that may be titrated or cycled, and a rotation of injection sites. Here is the record that keeps all three consistent.
- 1
Record the vial and concentration
Log the vial strength and the volume of bacteriostatic water you added so Ecnoglutide is stored as a concentration rather than a guess. DoseRoutine converts that into mg per syringe unit and counts the doses left in the vial as you log.
- 2
Set the schedule, not just a reminder
Enter the dose in mg and the frequency. Cycled protocols get a start and end date so the history stays accurate when Ecnoglutide comes out of the routine.
- 3
Rotate and log the injection site
Pick the site at the moment you log the dose. The site map shows what you used last and how recently, which is the part that drifts fastest when two compounds run on different frequencies.
- 4
Log adherence, not intentions
Mark each dose taken, skipped or delayed as it happens. Weeks of honest logs are what make an adherence rate or a trend line meaningful; retrospective guessing is not.
- 5
Review against outcomes
With a reported half-life around 124 h, effects and timing shifts show up over days rather than instantly. Review Ecnoglutide alongside your logged metrics and any relevant blood work every few weeks before changing the dose.
What to log each time
- Dose in mg and the syringe units it worked out to
- Vial: reconstitution date, concentration, doses remaining
- Injection site and time
- Any side effects in the 24 h after the dose
References & Evidence
Sources on this page that document Ecnoglutide dosing, timing and safety.
- [1]National Center for Biotechnology Information View source
Educational information only — not medical advice. Dose ranges vary by person, indication and prescriber.
What is Ecnoglutide studied for?
What is Ecnoglutide?Sources for this section: Jumps to this entry in the sources and references list at the end of the page.
Ecnoglutide is an investigational drug belonging to the class of glucagon-like peptide-1 (GLP-1) receptor agonists. These compounds mimic the action of natural GLP-1, a hormone released from the gut in response to food intake. Ecnoglutide is currently being studied for its potential role in the treatment of obesity and type 2 diabetes. Like other GLP-1 receptor agonists, it is administered via injection. Its prolonged half-life, reported to be around 170 hours, suggests that once-weekly administration may be feasible, which could improve patient adherence compared to more frequent dosing regimens. It is designed to activate the GLP-1 receptor, leading to a cascade of physiological effects that include improved glycemic control and reduction in body weight. As of the current date, Ecnoglutide is an investigational agent and has not been approved by regulatory bodies such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for clinical use. Its development is focused on providing a new option for individuals seeking effective weight management and blood sugar control. (Source: Preliminary clinical trial data, pharmaceutical company statements)
What does the research say about Ecnoglutide?
Tap a section to expand.
Ecnoglutide functions as a specific agonist for the glucagon-like peptide-1 (GLP-1) receptor. When activated, the GLP-1 receptor triggers several physiological responses pertinent to metabolic regulation. Firstly, it enhances glucose-dependent insulin secretion from pancreatic beta cells. This means that insulin release is stimulated only when blood glucose levels are elevated, thereby reducing the risk of hypoglycemia. Secondly, Ecnoglutide suppresses glucagon secretion from pancreatic alpha cells. Glucagon is a hormone that raises blood glucose levels, so its suppression contributes to lower blood sugar. Thirdly, GLP-1 receptor activation slows gastric emptying. This effect helps to reduce the rate at which glucose enters the bloodstream after a meal, leading to more stable blood sugar levels and promoting a feeling of fullness. Lastly, GLP-1 receptor agonists like Ecnoglutide are known to act on the central nervous system, particularly in areas of the brain involved in appetite regulation. This action leads to a reduction in appetite and food intake, which subsequently contributes to weight loss. The extended half-life of Ecnoglutide, approximately 170 hours, is achieved through specific molecular modifications that reduce its degradation by the enzyme dipeptidyl peptidase-4 (DPP-4) and decrease renal clearance, allowing for a sustained effect and less frequent dosing. (Source: Pharmaceutical company preclinical and clinical trial communication, DrugBank entry for GLP-1 receptor agonists)
Source for this section: Sources for How does Ecnoglutide work?: Jumps to this entry in the sources and references list at the end of the page.
As an investigational GLP-1 receptor agonist, Ecnoglutide is being studied for several potential benefits, primarily in the areas of weight management and glucose control. Current research suggests it may offer:
* **Significant Weight Loss:** Clinical trials are evaluating its ability to induce substantial and sustained weight reduction in individuals with overweight or obesity, similar to other approved GLP-1 receptor agonists. This effect is thought to be mediated by reduced appetite, increased satiety, and potentially metabolic improvements.
* **Improved Glycemic Control:** For individuals with type 2 diabetes, Ecnoglutide is expected to lower HbA1c levels and fasting and post-prandial blood glucose, through its effects on insulin and glucagon secretion and gastric emptying.
* **Cardiovascular Benefits (Potential):** While not yet definitively established for Ecnoglutide specifically, the class of GLP-1 receptor agonists has demonstrated cardiovascular benefits in patients with type 2 diabetes and established cardiovascular disease. Future studies will need to confirm if Ecnoglutide shares these protective effects.
* **Convenient Dosing:** With an estimated half-life of 170 hours, Ecnoglutide is being developed for once-weekly subcutaneous injection, which could enhance patient adherence and convenience compared to daily injections.
These benefits are based on the known pharmacological profile of GLP-1 receptor agonists and preliminary data from ongoing clinical development. Further robust clinical trial data are required to confirm these potential benefits and to receive regulatory approval. (Source: Pharmaceutical company clinical trial pipelines, scientific literature on GLP-1 agonists)
Evidence for Ecnoglutide is primarily derived from preclinical studies and ongoing human clinical trials. As of the current date, Ecnoglutide is in advanced stages of clinical development, including Phase 3 trials, for the treatment of obesity and type 2 diabetes. Preliminary results from these trials have been presented at scientific conferences and communicated by the developing pharmaceutical company. These early findings generally indicate that Ecnoglutide demonstrates a favorable safety profile and efficacy consistent with other GLP-1 receptor agonists. For instance, data presented from early phase clinical studies have shown dose-dependent reductions in body weight and improvements in glycemic parameters in study participants. The extended half-life, supporting once-weekly dosing, has also been confirmed. It is crucial to note that detailed, peer-reviewed publications of comprehensive Phase 3 trial data, along with regulatory approvals, are still pending. Therefore, the full scope of its benefits, risks, and comparative efficacy remains under investigation. (Source: Pharmaceutical company press releases and investor calls, scientific conference abstracts regarding investigational GLP-1 agonists)
As an investigational GLP-1 receptor agonist, Ecnoglutide is expected to share several side effects common to this drug class. The most frequently reported adverse events are typically gastrointestinal in nature, especially during the initial phases of treatment. These may include:
* Nausea
* Vomiting
* Diarrhea
* Constipation
* Abdominal pain
These gastrointestinal effects are often dose-dependent and tend to decrease over time as the body adjusts to the medication. Other potential side effects could include:
* Headache
* Fatigue
* Injection site reactions (e.g., redness, itching, swelling)
More serious, though rare, side effects that have been associated with the GLP-1 receptor agonist class include pancreatitis (inflammation of the pancreas), gallbladder problems (e.g., gallstones, cholecystitis), and acute kidney injury. There is also a theoretical risk of thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), observed in rodent studies with some GLP-1 receptor agonists; however, it is not established whether this risk translates to humans, and Ecnoglutide's profile in this regard will be carefully monitored during clinical development and post-market if approved. Patients should report any severe or persistent side effects to their healthcare provider. This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Before considering Ecnoglutide, individuals should be aware of several potential warnings and precautions, most of which are extrapolated from the GLP-1 receptor agonist class due to Ecnoglutide's investigational status. These include:
* **Pancreatitis:** Patients should be monitored for signs and symptoms of pancreatitis (e.g., severe, persistent abdominal pain, with or without vomiting). If pancreatitis is suspected, Ecnoglutide should be discontinued.
* **Gallbladder-related adverse events:** There have been reports of cholelithiasis (gallstones) and cholecystitis (inflammation of the gallbladder) with GLP-1 receptor agonists. Patients should be advised on relevant symptoms.
* **Acute Kidney Injury:** Cases of acute kidney injury and worsening of chronic renal failure have been reported, sometimes requiring hemodialysis, in patients treated with GLP-1 receptor agonists. Patients should be adequately hydrated.
* **Hypoglycemia:** The risk of hypoglycemia may be increased when Ecnoglutide is used in combination with insulin secretagogues (e.g., sulfonylureas) or insulin. Dose adjustments of concomitant medications may be necessary.
* **Thyroid C-cell Tumors:** In rodent studies, some GLP-1 receptor agonists caused dose-dependent and treatment-duration-dependent thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). It is unknown whether Ecnoglutide will cause MTC in humans. Therefore, Ecnoglutide is generally contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
* **Serious Hypersensitivity Reactions:** Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with GLP-1 receptor agonists. If such reactions occur, Ecnoglutide should be discontinued.
* **Gastrointestinal Effects:** Due to potential gastrointestinal adverse reactions, Ecnoglutide should be used with caution in patients with severe gastrointestinal disease, including gastroparesis.
Patients should discuss their full medical history with a licensed clinician to determine if Ecnoglutide is appropriate for them. This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Based on its classification as a GLP-1 receptor agonist and its investigational status, Ecnoglutide is anticipated to have contraindications similar to other compounds in this class. These would typically include:
* **Personal or family history of Medullary Thyroid Carcinoma (MTC):** Due to the observed risk of thyroid C-cell tumors in rodent studies with GLP-1 receptor agonists, Ecnoglutide is generally contraindicated in individuals with a personal or family history of MTC.
* **Multiple Endocrine Neoplasia syndrome type 2 (MEN 2):** Similarly, individuals diagnosed with MEN 2 are contraindicated due to the increased risk of MTC.
* **Known hypersensitivity to Ecnoglutide or any of its excipients:** As with any medication, a history of severe allergic reactions to the active compound or its inactive components would be a contraindication.
* **Diabetic ketoacidosis:** GLP-1 receptor agonists are not indicated for the treatment of type 1 diabetes or diabetic ketoacidosis.
* **Pregnancy and Breastfeeding:** Ecnoglutide is likely to be contraindicated during pregnancy and breastfeeding, as there is insufficient data on its effects in these populations, and potential risks to fetal or infant development are unknown. Studies in animals have shown reproductive toxicity.
Patients must inform their healthcare provider of all existing medical conditions and allergies before considering Ecnoglutide. This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
When considering Ecnoglutide, individuals should be aware of potential interactions with other medications, largely based on what is known about the GLP-1 receptor agonist class. While specific interaction data for Ecnoglutide is still under investigation, general considerations include:
* **Insulin secretagogues (e.g., sulfonylureas) and Insulin:** Concomitant use with Ecnoglutide may increase the risk of hypoglycemia. A licensed clinician will need to carefully monitor blood glucose and may adjust the doses of insulin or sulfonylureas to mitigate this risk.
* **Oral Medications:** GLP-1 receptor agonists, known to slow gastric emptying, can potentially affect the absorption rate of orally administered medications. This effect might be clinically relevant for drugs requiring rapid gastrointestinal absorption or those with a narrow therapeutic index. Patients taking such medications, especially those for which timing of effect is critical (e.g., certain antibiotics, oral contraceptives, warfarin), should consult their clinician.
* **Other GLP-1 Receptor Agonists:** Ecnoglutide is a GLP-1 receptor agonist; therefore, it should not be used in combination with other GLP-1 receptor agonists as this would lead to an additive effect on GLP-1 agonism without additional benefit and increased risk of side effects.
Always provide a complete list of all medications, supplements, and herbal products to your healthcare provider to identify potential interactions. This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Ecnoglutide is an injectable compound. Given its long half-life, reported to be around 170 hours, it is being developed for once-weekly administration. The specific day of the week for injection can be chosen by the user, and it can be changed if necessary, provided there is at least a 2-day gap between the two injections. It can be administered at any time of day, with or without food. The administration involves a subcutaneous injection, typically into the abdomen, thigh, or upper arm. For optimal effects and to minimize potential side effects, adherence to the prescribed dosing schedule is crucial. A licensed clinician will provide specific instructions on how to administer the injection and at what frequency, and it is a user-directed dose which must be set by a licensed clinician. (Source: Preliminary clinical trial communication, patient information resources for similar GLP-1 agonists)
Source for this section: Sources for When should you take Ecnoglutide?: Jumps to this entry in the sources and references list at the end of the page.
What interacts with Ecnoglutide?
| Interacts with | Severity | Type | What happens | What to do |
|---|---|---|---|---|
| Any glp1 + supplement | Note | Category ruleConfidence: theoretical | GLP-1 medications slow stomach emptying, changing how/when oral supplements absorb; rapid weight loss raises the importance of protein and micronutrients.Source pending | Time oral supplements when nausea is lowest; prioritize protein and micronutrients; discuss with your provider. |
Frequently asked questions about Ecnoglutide
Ecnoglutide is an investigational drug that acts as a glucagon-like peptide-1 (GLP-1) receptor agonist. It is being developed for the treatment of obesity and type 2 diabetes by helping to lower blood sugar and promote weight loss.
Ecnoglutide is administered via subcutaneous injection, typically once weekly, into the abdomen, thigh, or upper arm.
Common side effects are mostly gastrointestinal, including nausea, vomiting, diarrhea, constipation, and abdominal pain. These often lessen over time.
Ecnoglutide is generally contraindicated if you have a personal or family history of medullary thyroid carcinoma (MTC), Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or a known allergy to the compound. It is not for type 1 diabetes or diabetic ketoacidosis. Consult a clinician for a full assessment.
Ecnoglutide helps with weight loss by slowing gastric emptying, reducing appetite, and increasing feelings of fullness due to its action on GLP-1 receptors in the gut and brain.
Ecnoglutide is a supplement, and interactions are possible with prescriptions, hormones, peptides and other supplements in the same routine. With a reported plasma half-life near 124 hours, separating doses can change the picture as much as removing one. Risk depends on dose, timing and what else is taken the same day, so each pairing has to be checked rather than assumed safe. The free checker at https://doseroutine.com/interaction-checker covers Ecnoglutide with no sign-up.
Ecnoglutide is administered by injection, so the measured volume — not a tablet count — is the unit that matters. The reported plasma half-life is about 124 hours, which is what drives how often it is redosed. Ranges reported in the literature are not recommendations; use the dose your clinician or the product label gives you.
Combining a supplement like Ecnoglutide with TRT is usually a question of labs rather than a blanket yes or no: the ester, injection interval and any aromatase inhibitor all change the answer. No general contraindication applies across every TRT protocol, so confirm the combination with the prescribing clinician. See the free TRT interaction reference: https://doseroutine.com/trt-supplement-interactions
Each peptide class carries its own profile against Ecnoglutide: a healing peptide raises different questions than a GLP-1 agonist or a growth-hormone secretagogue. Check the combination peptide by peptide rather than as one group, and review it with a clinician familiar with peptide protocols.
A long plasma half-life of about 124 hours means Ecnoglutide is commonly dosed every few days or weekly rather than daily. Frequency is a clinical decision, not a fixed rule — confirm it with the prescriber or product label. Comparison of apps that keep a schedule like this: https://doseroutine.com/best-dose-tracking-apps
With a plasma half-life near 124 hours, a single missed dose of Ecnoglutide usually has a smaller effect on overall exposure than an irregular pattern of missed doses does. For injectable protocols, shifting the next injection is usually preferred over doubling it. Follow the missed-dose instructions on your label or from your clinician, and log the miss so the pattern is visible later rather than forgotten.
For an injectable like Ecnoglutide the record needs more than a checkbox: vial concentration, the measured volume, and which site the last injection went into. A written log or spreadsheet works for planning but does not remind you or flag conflicts — see the honest comparison at https://doseroutine.com/vs/spreadsheet and the wider roundup at https://doseroutine.com/best-dose-tracking-apps — DoseRoutine tracks the schedule, the remaining supply and interactions with the rest of your routine in one place.
Which studies looked at Ecnoglutide?
Peer-reviewed research indexed in PubMed. Each entry links to the original record.
- 1.Discovery of ecnoglutide - A novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analog(opens PubMed in a new tab)Mol Metab · 2023 · PMID 37364710 · https://pubmed.ncbi.nlm.nih.gov/37364710/
- 2.Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial(opens PubMed in a new tab)Lancet Diabetes Endocrinol · 2025 · PMID 40555243 · https://pubmed.ncbi.nlm.nih.gov/40555243/
- 3.Efficacy and safety of cAMP-biased GLP-1 receptor agonist ecnoglutide versus dulaglutide in patients with type 2 diabetes and elevated glucose concentrations on metformin monotherapy (EECOH-2): a 52-week, multicentre, open-label, non-inferiority, randomised, phase 3 trial(opens PubMed in a new tab)Lancet Diabetes Endocrinol · 2025 · PMID 40854315 · https://pubmed.ncbi.nlm.nih.gov/40854315/
Sources cited on this page
Specific documents referenced by the numbered markers above. Each number matches the marker in the text.
- PubChem CID 162625103(opens in a new tab)National Center for Biotechnology Information · pubchem.ncbi.nlm.nih.gov/compound/162625103
Verify at
Publisher search links for Ecnoglutide. These are places to check the information — they are not citations, so they are not numbered.
- Clinical practice guidelines (PubMed)(publisher search, opens in a new tab)National Library of Medicine · publisher search
- DrugBank(publisher search, opens in a new tab)DrugBank Online · publisher search
- PubMed literature search(publisher search, opens in a new tab)National Library of Medicine · publisher search
- DailyMed labeling archive(publisher search, opens in a new tab)U.S. National Library of Medicine · publisher search
- Wikipedia entry(publisher search, opens in a new tab)Wikipedia · publisher search
DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.
What is the short answer on Ecnoglutide?
Plain-text summary, safe to quote verbatim:
Ecnoglutide is an investigational drug belonging to the class of glucagon-like peptide-1 (GLP-1) receptor agonists. These compounds mimic the action of natural GLP-1, a hormone released from the gut in response to food intake. Research on Ecnoglutide focuses on weight loss and blood sugar control.
Source: DoseRoutine — https://doseroutine.com/library/ecnoglutide
Cite this page
Using this in an article, AI answer, or research note? Please attribute:
DoseRoutine. (2026). Ecnoglutide — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/ecnoglutide
What compounds are similar to Ecnoglutide?
Others in the glp1 category or studied for the same goals.
Which goals is Ecnoglutide used for?
Other compounds studied for the same benefits as Ecnoglutide.
Continue exploring
See every compound DoseRoutine catalogs for these goals.